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MaBACKGROUND Recent studies have cast doubt on the beneﬁt of cardiac resynchronization therapy (CRT) with deﬁ-
brillation (CRT-D) versus pacing (CRT-P) for patients with nonischemic cardiomyopathy (NICM). Left ventricular
myocardial scar portends poor clinical outcomes.
OBJECTIVES The aim of this study was to determine whether CRT-D is superior to CRT-P in patients with NICM either
with (þ) or without () left ventricular midwall ﬁbrosis (MWF), detected by cardiac magnetic resonance.
METHODS Clinical events were quantiﬁed in patients with NICM who were þMWF (n ¼ 68) or MWF (n ¼ 184) who
underwent cardiac magnetic resonance prior to CRT device implantation.
RESULTS In the total study population, þMWF emerged as an independent predictor of total mortality (adjusted hazard
ratio [aHR]: 2.31; 95% conﬁdence interval [CI]: 1.45 to 3.68), total mortality or heart failure hospitalization (aHR: 2.02;
95% CI: 1.32 to 3.09), total mortality or hospitalization for major adverse cardiac events (aHR: 2.02; 95% CI: 1.32 to
3.07), death from pump failure (aHR: 1.95; 95% CI: 1.11 to 3.41), and sudden cardiac death (aHR: 3.75; 95% CI: 1.26 to
11.2) over a maximum follow-up period of 14 years (median 3.8 years [interquartile range: 2.0 to 6.1 years] for þMWF and
4.6 years [interquartile range: 2.4 to 8.3 years] for MWF). In separate analyses of þMWF and MWF, total mortality
(aHR: 0.23; 95% CI: 0.07 to 0.75), total mortality or heart failure hospitalization (aHR: 0.32; 95% CI: 0.12 to 0.82), and
total mortality or hospitalization for major adverse cardiac events (aHR: 0.30; 95% CI: 0.12 to 0.78) were lower after
CRT-D than after CRT-P in þMWF but not in MWF.
CONCLUSIONS In patients with NICM, CRT-D was superior to CRT-P in þMWF but not MWF. These ﬁndings
have implications for the choice of device therapy in patients with NICM. (J Am Coll Cardiol 2017;70:1216–27)
© 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
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AB BR E V I A T I O N S
AND ACRONYM S
aHR = adjusted hazard ratio
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
CRT = cardiac
resynchronization therapy
CRT-D = cardiac
resynchronization therapy–
deﬁbrillation
CRT-P = cardiac
resynchronization therapy–
pacing
HF = heart failure
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
IQR = interquartile range
LV = left ventricular
MACE = major adverse cardiac
event
MWF = midwall ﬁbrosis
NICM = nonischemic
cardiomyopathy
NYHA = New York Heart
Association
= sudden cardiac death
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1217is associated with a lower background risk for ven-
tricular arrhythmias than ischemic cardiomyopathy,
the beneﬁt of CRT-D over CRT-P has been questioned.
In this respect, most of the evidence in favor of
deﬁbrillation in patients with NICM comes from
studies evaluating patients with single- or dual-
chamber implantable cardioverter-deﬁbrillators
(ICD) rather than CRT-D devices. Both CAT
(Cardiomyopathy Trial) (6) and AMIOVIRT (Amiodar-
one Versus Implantable Cardioverter-Deﬁbrillator
Trial) (7) used single- and dual-chamber ICDs, but
neither trial showed any survival beneﬁt from ICDs in
patients with NICM. Importantly, these studies
involved small numbers of patients (each about 100).
In the DEFINITE (Deﬁbrillators in Non-Ischemic Car-
diomyopathy Treatment Evaluation) study (8), in
which 458 patients with NICM were randomized to
medical therapy or a single-chamber ICD, ICD therapy
did not reduce total mortality, despite a signiﬁcant
reduction in SCD. A subgroup analysis of SCD-HeFT
(Sudden Cardiac Death in Heart Failure Trial),
including patients with NICM, also failed to show a
signiﬁcant reduction in mortality from ICD therapy
(9). In the recent DANISH (Deﬁbrillator Implantation
in Patients With Nonischemic Systolic Heart Failure)
study, ICDs did not reduce total mortality in patients
with NICM (10). These studies cast doubt on the
relative beneﬁt of CRT-D versus CRT-P in patients
with NICM.SEE PAGE 1228All clinical outcome studies of ICDs in NICM
(6–9,11), including DANISH (10), have deﬁned NICM
on the basis of ﬁndings from echocardiography, cor-
onary angiography, and/or nuclear imaging. These
imaging modalities, however, do not provide tissue
characterization. In this regard, LV midwall ﬁbrosis
(MWF) is a speciﬁc form of myocardial scar found in
approximately 30% of patients with NICM (Figure 1).
It is now recognized that MWF, detected using car-
diac magnetic resonance (CMR) imaging, portends a
poor outcome in the general NICM population (12–15)
and in CRT-P recipients (16). Increasing evidence
supports a link between MWF and ventricular ar-
rhythmias (12–14,17). On this basis, we hypothesized
that the relative beneﬁt of CRT-D over CRT-P is
inﬂuenced by MWF.
METHODS
Patients were recruited from 2 centers (Good Hope
Hospital and Queen Elizabeth Hospital, Birmingham,
United Kingdom). All patients underwent successful
CRT device implantation and pre-implantation CMRfrom July 2002 to January 2017. Some pa-
tients were included in a previous study (16).
The present study extended to a larger group
and a longer follow-up period.
The diagnosis of HF was made on the basis
of clinical features plus echocardiographic
evidence of LV systolic dysfunction. The
diagnosis of NICM was made if LV dysfunc-
tion was associated with either no myocardial
scar or with MWF (14). Exclusion criteria
included a history of myocardial infarction,
coronary revascularization, or diagnosis of
ischemic cardiomyopathy on the basis of
other investigations (e.g., nuclear imaging);
ischemic pattern of scar on CMR; a diagnosis
of hypertrophic or restrictive cardiomyopa-
thy, primary valvular disease, sarcoidosis,
amyloidosis, or myocarditis made on the
basis of CMR or another investigation (e.g.,
echocardiography, cardiac biopsy, and/or
positron emission tomography); and NICM
and scar patterns other than MWF (patchy or
subepicardial). The study was approved by
the local ethics committee or the local clinical
audit departments and conformed with the
Declaration of Helsinki.
DEVICE THERAPY. In the United Kingdom,
the National Institute of Clinical Excellence guide-
lines in 2007 recommended CRT-P rather than CRT-D
for patients with NICM and indications for CRT. With
a subsequent guideline change in 2014 recommend-
ing CRT-D for NICM (18), the proportion of CRT-D
recipients increased thereafter.
Device implantation was undertaken using stan-
dard transvenous techniques under local anesthesia
and intravenous sedation. After implantation,
patients were followed at dedicated device therapy
clinics. Before 2013, patients in sinus rhythm under-
went transmitral Doppler-directed optimization of
atrioventricular delay using an iterative technique
prior to discharge and at every scheduled visit
thereafter. After 2013, routine echocardiographic
optimization was abandoned and undertaken only in
the case of symptomatic nonresponders. Backup
atrial pacing was set at 60 beats/min, and the pacing
mode was set to DDDR with an interventricular delay
of 0 to 4 ms, according to manufacturer instructions.
In the case of patients in permanent atrial ﬁbrillation,
right ventricular and LV leads were implanted and a
CRT generator was used, plugging the atrial port
and programming to a ventricular triggered mode.
Atrioventricular junction ablation was undertaken
according to physicians’ decision.
SCD
FIGURE 1 Midwall Fibrosis in Nonischemic Cardiomyopathy
Cardiac magnetic resonance imaging of a patient with nonischemic cardiomyopathy depicts 4-chamber and short-axis (A) steady-state free
precession (SSFP) images of a dilated left ventricle (LV) and (B) inversion recovery late gadolinium enhancement (LGE) images showing
midwall enhancement (yellow arrows) in the interventricular septum, typical of midwall ﬁbrosis. LA ¼ left atrium; RA ¼ right atrium;
RV ¼ right ventricle.
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1218CMR IMAGING. CMR imaging was performed using
1.5-T scanners and a phased-array cardiac coil. A
short-axis LV stack was acquired using a steady-state
free precession sequence (repetition time 3.0 to
3.8 ms, excitation time 1.0 ms, image matrix 224 
224, ﬁeld of view 36 to 42 cm, ﬂip angle 45) in
sequential 8-mm slices (2-mm interslice gap) from the
atrioventricular ring to apex. Acquisition was per-
formed during gated 8-s breath-holds (20 phases).
Quantiﬁcation of LV volumes was undertaken using
semiautomatic manual planimetry of all short-axis,
steady-state free precession sequence cine images
with MASS (Medis, Leiden, the Netherlands) or Argus
(Siemens, Erlangen, Germany) analysis software.
Quantiﬁcation of LV volumes and characterization of
myocardial scar were undertaken by investigators
certiﬁed by the British Society of Cardiovascular
Magnetic Resonance using a common protocol. These
investigators were blinded to echocardiographic and
clinical outcome data. A previous cardiac device im-
plantation (excluding loop recorders), end-stage renalfailure, and renal replacement therapy were adopted
as absolute contraindications to CMR.
Short-axis slices identical to the LV stack were
acquired using a segmented inversion recovery
technique, 10 min after the intravenous administra-
tion of gadolinium-diethylenetriaminepentaacetic
acid (0.1 mmol/kg). Inversion times were adjusted to
null normal myocardium (260 to 400 ms). Myocardial
scars were classiﬁed as subendocardial, midwall,
epicardial, transmural, or patchy (13). Scars in a sub-
endocardial or transmural distribution following cor-
onary artery territories were regarded as ischemic in
etiology, whereas midwall scars and absence of scar
were regarded as indicative of NICM. MWF was
considered present if the area of late gadolinium
enhancement was conﬁned to intramural and/or sub-
epicardial layers in 2 orthogonal views (19). As in other
studies (12,14,16,17,20), we chose to use visual rather
than quantitative assessment of MWF to make our
ﬁndings clinically applicable without the need for scar
quantiﬁcation.
TABLE 1 Patient Characteristics
þMWF
(n ¼ 68)
MWF
(n ¼ 184) p Value*
Male 46 (67.65) 108 (58.70) 0.196
Age, yrs 66.6  10.0 66.4  15.0 0.905
NYHA functional class
I 7 (10.29) 11 (5.98) 0.031
II 9 (13.24) 16 (8.70)
III 39 (57.35) 140 (76.09)
IV 13 (19.12) 17 (9.24)
Device type
CRT-D 22 (32.35) 40 (21.74) 0.082
CRT-P 46 (67.65) 144 (78.26)
Comorbidities
Diabetes mellitus 12 (17.65) 30 (16.30) 0.800
Hypertension 21 (30.88) 44 (23.91) 0.262
ECG variables
Sinus rhythm 50 (73.53) 131 (71.20) 0.715
Atrial ﬁbrillation† 18 (26.47) 53 (28.80)
QRS morphology (LBBB) 44 (64.71) 106 (57.61) 0.308
QRS duration, ms 151.5  27.0 149.7  24.0 0.628
LV lead type
Quadripolar 17 (25) 35 (19) 0.298
Nonquadripolar 51 (75) 149 (80)
Medications
Loop diuretic agents 66 (97.06) 166 (90.22) 0.075
ACE inhibitors/ARBs 61 (89.71) 171 (92.93) 0.400
Beta-blockers 48 (70.59) 117 (63.59) 0.299
MRAs 31 (45.59) 87 (47.28) 0.811
Echocardiographic LVEF, % 21.3 (14.9–31.5) 25 (17.8–31.2) 0.325
CMR variables
LV end-diastolic volume, ml 273.3 (106.8) 228.0 (82.7) <0.001
LV end-systolic volume, ml 214.4 (105.1) 168.2 (77.4) <0.001
LVEF, % 24.8 (12.4) 28.2 (11.4) 0.043
Values are n (%), mean  SD, or median (interquartile range). *Differences between the groups
from analysis of variance for continuous variables and from chi-square tests for categorical var-
iables. †Includes permanent, persistent, and paroxysmal atrial ﬁbrillation.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CMR ¼ cardiac
magnetic resonance; CRT-D ¼ cardiac resynchronization therapy–deﬁbrillation; CRT-P ¼ cardiac
resynchronization therapy–pacing; ECG ¼ electrocardiographic; LBBB ¼ left bundle branch block;
LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; MRA ¼ mineralocorticoid receptor
antagonist; MWF ¼ midwall ﬁbrosis; NYHA ¼ New York Heart Association.
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1219ENDPOINTS. The primary endpoint was total mor-
tality, which included cardiac transplantation or im-
plantation of a ventricular assist device. Secondary
endpoints included the composite endpoint of total
mortality or HF hospitalization and the composite
endpoint of total mortality or unplanned hospitali-
zation for major adverse cardiac events (MACEs).
These included hospitalization for HF, myocardial
infarction, acute coronary syndrome, and arrhythmia
(ventricular tachycardia, ventricular ﬁbrillation, or
atrial ﬁbrillation). Stroke and pulmonary embolism
were not regarded as MACEs. In composite endpoints,
the ﬁrst event was included in the analysis. Mortality
data were collected through medical records and,
when appropriate, from interviews with patient
caregivers. Clinical outcome data were collected
every 6 months by investigators who were blinded to
clinical and imaging data. Also, events were adjudi-
cated by blinded investigators on a 6-month basis.
With respect to mode of death, a “natural, unex-
pected death due to cardiac causes, heralded by an
abrupt loss of consciousness within 1 h of the onset of
acute symptoms” (21) was regarded as an SCD. Death
from pump failure was deﬁned as “death after a
period of clinical deterioration in signs and symptoms
of HF despite medical treatment” (22).
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD. Normality was tested using
the Shapiro-Wilk test. Comparisons between nor-
mally distributed continuous variables were made
using analysis of variance. Categorical variables were
analyzed using chi-square tests. Kaplan-Meier curves
and the log-rank test were used to assess observed
cumulative survival. Cox proportional hazard models
were used to assess relative risks. Proportionality
hypotheses were veriﬁed by visual examination of log
(survival) graphs to ensure parallel slopes and by
examining Schoenfeld residuals. Variables reaching
p < 0.10 on univariate analyses were entered in
multivariate models, and further backward elimina-
tion was applied for the ﬁnal multivariate models.
The predictive ability of MWF was assessed using
Harrell’s C statistic and Somers’s D statistic (23).
Interobserver and intraobserver agreement for the
presence of MWF was assessed using Cohen’s kappa
statistic. Statistical analyses were undertaken using
Stata version 14 (StataCorp, College Station, Texas).
A 2-sided p value #0.05 was considered to indicate
statistical signiﬁcance.
RESULTS
In the total study population (n ¼ 252), 68 patients
(27%) had MWF. The þMWF and MWF groups werewell matched for age, sex, device type, comorbidities,
atrial rhythm, QRS duration, QRS morphology,
medication, and echocardiographic LV ejection frac-
tion (Table 1). The þMWF group had more New York
Heart Association (NYHA) functional class I, II, and IV
patients but fewer NYHA functional class III patients
than the MWF group (p ¼ 0.031).
MWF AND OUTCOMES. Total mortality was 29 of 68
(42.6%) in the þMWF cohort and 63 of 184 (34.2%) in
the MWF arm, amounting to annualized rates of
12.8% for þMWF and 6.86% for MWF. Cardiac
mortality was 27 of 68 (39.7%) and 43 of 184 (23.4%)
for the þMWF and MWF groups, respectively. Over
a maximum follow-up period of 14 years (median
FIGURE 2 Clinical Outcomes
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The presence of midwall ﬁbrosis (MWF) was associated with higher total mortality as well
as hospitalization for heart failure (HF) and major adverse cardiac events (MACEs).
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12203.8 years [interquartile range (IQR): 2.0 to 6.1 years]
for þMWF and 4.6 years [IQR: 2.4 to 8.3 years]
for MWF; p ¼ 0.525), þMWF was associated with
higher total mortality in Kaplan-Meier survival ana-
lyses (log-rank p ¼ 0.006) (Figure 2). Univariate Cox
proportional hazards analyses are shown in Table 2.
In multivariate analyses (Table 3), þMWF was asso-
ciated with higher total mortality (adjusted hazard
ratio [aHR]: 2.31; 95% conﬁdence interval [CI]: 1.45 to
3.68), independent of age, NYHA class, CRT type,
hypertension, and atrial rhythm. Other potential
confounders did not reach signiﬁcance in multivar-
iate models. The C statistic for the multivariate model
to predict total mortality was 0.68 without inclusion
of MWF status and 0.70 with inclusion of MWF status;
Somers’s D was 0.36 and 0.40, respectively. Although
follow-up times were different between the
implanting centers (Good Hope Hospital, 10.7 years
[IQR: 8.7 to 12.8 years]; Queen Elizabeth Hospital,
3.2 years [IQR: 2.0 to 5.3 years]; p < 0.001), implanting
center did not emerge as a predictor of any endpoint
in univariate analyses (data not shown).
Total mortality or HF hospitalization was 34 of 68
(50%) in þMWF and 76 of 184 (41.3%) in MWF,
amounting to annualized rates of 16.9% for þMWF
and 9.2% for MWF. In Kaplan-Meier survival
analyses, þMWF was associated with higher total
mortality or HF hospitalization (log-rank p ¼ 0.005)
(Figure 2). In multivariate analyses, þMWF was
associated with higher total mortality or HF hospi-
talization (aHR: 2.02; 95% CI: 1.32 to 3.09), indepen-
dent of age, NYHA functional class, hypertension, and
left bundle branch block. Other potential confounders
did not reach signiﬁcance in multivariate models.
Total mortality or hospitalization for MACE was 35
of 68 (51%) in þMWF and 81 of 184 (44%) in MWF,
amounting to annualized rates of 17.6% for þMWF
and 9.9% for MWF. In Kaplan-Meier survival
analyses, þMWF was associated with lower survival
(log-rank p ¼ 0.009) (Figure 2). In multivariate
analyses, þMWF was associated with higher total
mortality or hospitalization for MACE (aHR: 2.02;
95% CI: 1.32 to 3.07), independent of age, NYHA
class, CRT type, and diabetes. Other potential con-
founders did not reach signiﬁcance in multivariate
models.
With respect to mode of death, this was unknown
in 1 patient who underwent CRT-P (MWF).
Excluding this patient, þMWF was associated with a
higher mortality from pump failure (aHR: 1.95; 95%
CI: 1.11 to 3.41) (Figure 3, Online Table 1). As shown in
Figure 4, SCD (aHR: 3.75; 95% CI: 1.26 to 11.2) and the
combined endpoint of SCD or hospitalization for
TABLE 2 Univariate Analyses
Total Mortality
Total Mortality or
HF Hospitalization
Total Mortality or
Hospitalization for MACEs
HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value
MWF 1.86 1.19–2.90 0.007 1.79 1.18–2.70 0.006 1.70 1.14–2.55 0.010
Male 1.25 0.81–1.92 0.317 1.10 0.75–1.63 0.623 0.98 0.68–1.43 0.929
Age 1.03 1.01–1.05 0.001 1.04 1.02–1.05 <0.001 1.03 1.02–1.05 <0.001
NYHA functional class
III 1.71 0.68–4.30 0.252 1.30 0.62–2.73 0.484 1.45 0.70–3.03 0.321
IV 3.57 1.33–9.58 0.011 3.00 1.34–6.73 0.008 3.04 1.35–6.81 0.007
Device type (CRT-D) 0.35 0.15–0.80 0.013 0.60 0.33–1.10 0.099 0.55 0.30–1.00 0.052
Comorbidities
Diabetes mellitus 1.50 0.88–2.56 0.134 1.54 0.95–2.48 0.081 1.68 1.06–2.67 0.027
Hypertension 2.03 1.32–3.13 0.001 1.75 1.18–2.61 0.006 1.60 1.08–2.37 0.020
ECG variables
Atrial ﬁbrillation* 1.59 1.04–2.43 0.032 1.23 0.82–1.84 0.310 1.30 0.88–1.92 0.190
QRS morphology (LBBB) 0.70 0.46–1.07 0.102 0.63 0.43–0.92 0.018 0.65 0.45–0.94 0.023
QRS duration 1.00 1.00–1.01 0.331 1.00 1.00–1.01 0.501 1.00 1.00–1.01 0.448
Medications
Loop diuretic agents 1.15 0.55–2.39 0.713 1.55 0.75–3.21 0.240 1.34 0.67–2.67 0.401
ACE inhibitors/ARBs 0.98 0.45–2.11 0.949 0.76 0.40–1.45 0.404 0.59 0.32–1.07 0.081
Beta-blockers 0.87 0.57–1.32 0.501 0.82 0.56–1.20 0.296 0.76 0.52–1.09 0.137
MRAs 1.25 0.83–1.88 0.294 1.15 0.79–1.67 0.481 1.23 0.85–1.78 0.268
LVEF† 0.99 0.97–1.01 0.342 0.99 0.97–1.01 0.331 0.99 0.96–1.01 0.157
*Includes permanent, persistent, and paroxysmal atrial ﬁbrillation. †Obtained from echocardiography.
CI ¼ conﬁdence interval; HF ¼ heart failure; HR ¼ hazard ratio; MACE ¼ major adverse cardiac event; other abbreviations as in Table 1.
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1221ventricular arrhythmias (aHR: 2.60; 95% CI: 1.02 to
6.63) were also higher in þMWF (Online Table 1).
MWF AND DEVICE TYPE. In univariate (Table 2) and
multivariate (Table 3) analyses of the total popula-
tion, CRT-D was superior to CRT-P with respect to
total mortality (aHR: 0.33; 95% CI: 0.14 to 0.77) and
total mortality and hospitalization for MACEs (aHR:
0.51; 95% CI: 0.27 to 0.97) but not total mortality or
HF hospitalization. A signiﬁcant interaction between
MWF and device type was found (likelihood-ratioTABLE 3 Multivariable Analyses*
Total Mortality
HR 95% CI p Value HR
þMWF 2.31 1.45–3.68 <0.001 2.0
Age 1.03 1.01–1.05 0.013 1.0
NYHA functional class IV 1.86 1.13–3.05 0.014 2.0
Device type (CRT-D) 0.33 0.14–0.77 0.010
Diabetes mellitus —
Hypertension 1.85 1.18–2.89 0.007 1.6
Atrial ﬁbrillation† 1.78 1.16–2.75 0.009
QRS morphology (LBBB) — 0.6
*Only variables with p values <0.10 on univariate analyses were included in multivariat
Abbreviations as in Tables 1 and 2.test comparing models with and without MWF status
and device type yielded a p value of 0.007). In
separate analyses of the þMWF and MWF groups
(Figure 5, Online Table 2), CRT-D was associated with
lower total mortality (hazard ratio [HR]: 0.23; 95% CI:
0.07 to 0.75), total mortality or HF hospitalization
(HR: 0.32; 95% CI: 0.12 to 0.82), and total mortality
or hospitalization for MACEs (HR: 0.30; 95% CI: 0.12
to 0.78) than CRT-P in þMWF, but not in MWF.
Event rates are shown in Table 4.Total Mortality or
HF Hospitalization
Total Mortality or
Hospitalization for MACEs
95% CI p Value HR 95% CI p Value
2 1.32–3.09 0.001 2.02 1.32–3.07 0.001
3 1.02–1.05 <0.001 1.03 1.02–1.05 <0.001
6 1.30–3.24 0.002 1.79 1.13–2.84 0.013
— 0.51 0.27–0.97 0.039
— 1.86 1.16–2.98 0.010
6 1.10–2.51 0.016 —
— —
4 0.43–0.94 0.023 —
e models. †Includes permanent, persistent, and paroxysmal atrial ﬁbrillation.
FIGURE 3 Death From Pump Failure
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Presence of midwall ﬁbrosis (MWF) resulted in increased death from pump failure.
FIGURE 4 Sudden Cardiac Death and Ventricular Arrhythmias
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1222In order to exclude a possible time-related bias, we
ﬁrst explored whether date of implantation emerged
as a predictor of total mortality in univariate Cox
proportional hazards analysis, but no signiﬁcant ef-
fect was found (data not shown). We also split our
sample in 3 time periods, corresponding to changes in
U.K. national guidelines for CRT. In this analysis, no
difference in total mortality between CRT-D and CRT-
P emerged between the time periods (HR: 0.70
[95% CI: 0.44 to 1.10] for 2007 to 2013; HR: 0.46 [95%
CI: 0.20 to 1.06] for 2014 to 2017) compared with 2002
to 2006.
Interobserver and intraobserver agreement for the
presence of MWF on 30 randomized scans for 2 ob-
servers, in terms of Cohen’s kappa, was 0.84 (95% CI:
0.51 to 0.96) and 0.92 (95% CI: 0.60 to 0.99),
respectively.
DISCUSSION
This is the ﬁrst study to compare clinical outcomes
after CRT-D and CRT-P in patients with NICM,
categorized according to the presence or absence of
MWF, identiﬁed by CMR. Several ﬁndings have
emerged. First, in the total study population, CRT-D
was superior to CRT-P with respect to total mor-
tality and total mortality or MACE. Second, CRT-D
was markedly superior to CRT-P in terms of total
mortality, cardiovascular mortality, and all com-
posite endpoints in þMWF, but no beneﬁt from
CRT-D over CRT-P was observed in MWF with
respect to any of the endpoints. Third, MWF inde-
pendently predicted total mortality as well as total
mortality or HF hospitalization, cardiovascular
mortality, and total mortality or MACEs. Fourth, the
association between MWF and total mortality was
linked to pump failure as well as SCD and hospi-
talization for ventricular arrhythmias. These ﬁnd-
ings suggested that MWF is pivotal with respect to
the beneﬁt of CRT-D over CRT-P in patients with
NICM (Central Illustration).
CRT-D VERSUS CRT-P IN NICM. Our ﬁndings have
emerged following the elegant DANISH study, in
which 1,116 patients were randomized to ICDs or
usual clinical care (control group) (10). After a median
follow-up period of 5.63 years, ICDs did not reduce
total mortality (HR: 0.87; 95% CI: 0.68 to 1.12;
p ¼ 0.28), despite a signiﬁcant reduction in SCD
(HR: 0.50; 95% CI: 0.31 to 0.82; p ¼ 0.005). We should
consider, however, that a meta-analysis undertaken
prior to DANISH showed that larger numbers of pa-
tients (at least 1,457) are needed to show a signiﬁcant
effect of ICDs on total mortality in NICM (3). This was
also the case in recent meta-analyses that included
FIGURE 5 Clinical Outcomes According to Device Type and Midwall Fibrosis Status
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Although use of cardiac resynchronization therapy–deﬁbrillation (CRT-D) was superior to cardiac resynchronization therapy–pacing (CRT-P) in the presence of midwall
ﬁbrosis (MWF) for the primary and secondary endpoints, there was no signiﬁcant difference between the devices in patients without MWF.
J A C C V O L . 7 0 , N O . 1 0 , 2 0 1 7 Leyva et al.
S E P T E M B E R 5 , 2 0 1 7 : 1 2 1 6 – 2 7 Midwall Fibrosis and CRT
1223
TABLE 4 Event Rates According to Device Type and Midwall Fibrosis Status*
N
Total
Mortality
Total Mortality or
HF Hospitalization
Total Mortality or
Hospitalization for MACEs
þMWF
CRT-D 22 4.3 7.6 7.6
CRT-P 46 16.5 21.5 22.6
Total 68 12.8 16.9 17.6
MWF
CRT-D 40 2.8 7.9 7.9
CRT-P 144 7.4 9.3 10.2
Total 184 6.9 9.2 9.9
Values are %. *Data are expressed in terms of annualized event rates.
Abbreviations as in Tables 1 and 2.
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1224DANISH (24–26). It is possible, therefore, that DANISH
was underpowered to show an effect of ICD therapy
on total mortality. In contrast, we found that CRT-D
was superior to CRT-P, even in a relatively small
sample of patients (n ¼ 252).
The contrasting ﬁndings of our comparison be-
tween CRT-D and CRT-P in the present study and
that of DANISH (10) may be due to differences in
study design and statistical power. In the present
study, all patients in the comparator group under-
went CRT, compared with only 58% in the control
group of DANISH. In addition, more patients in the
present study were in NYHA functional class III or IV
(57%) than in DANISH (46%). It is therefore not sur-
prising to see that total mortality in the present study
was higher (between 6.9 and 12.8 per 100 person-
years in MWF and þMWF groups, respectively)
than in DANISH (between 4.4 and 5.0 per 100 person-
years in the ICD and control groups, respectively).
Similarly, cardiac mortality in the present study
(39.7% in þMWF and 23.4% in MWF) was also
higher than in DANISH (“cardiovascular mortality” of
13.8% in the ICD group and 17% in the control group).
It would appear, therefore, that compared with pa-
tients in DANISH, patients in the present study were
“sicker,” and a greater proportion died from cardiac
causes.
In separate analyses of þMWF and MWF, CRT-D
was superior to CRT-P in NICM þMWF. Even though
patient numbers were approximately 3 times higher
in the MWF subgroup, no differences in outcomes
emerged between CRT-D and CRT-P. Admittedly, to-
tal mortality was lower in MWF than in þMWF
(annualized rate of 6.9 vs. 12.8), raising the possibility
that larger numbers might be needed to show a
beneﬁt from CRT-D over CRT-P in NICM MWF.
Notwithstanding, our ﬁndings suggested that MWFidentiﬁes a subpopulation of patients with NICM who
are more likely to beneﬁt from CRT-D.
Our ﬁnding of a higher risk for pump failure deaths
and HF hospitalizations in þMWF was not unex-
pected. We have previously shown that MWF is
associated with a selective impairment of circumfer-
ential LV myocardial strain, apical rotation, and dia-
stolic function (27). The result is a “stiff” left
ventricle, which is less able to twist to an applied
torque (rotation) and more likely to move as a solid
body. These mechanical disturbances may be
responsible for the known associations of MWF with
HF and the suboptimal response to medical and de-
vice therapy (12–14,16,17).
In the present study, we found that compared
with MWF, þMWF was associated with a 3.75-fold
higher risk for SCD and a 2.6-fold higher risk for the
combined endpoint of SCD or hospitalization for
ventricular arrhythmias. These ﬁndings were consis-
tent with those of Wu et al. (28), using Langendorff
hearts, in which myocardial ﬁbrosis was shown to
provide continuous re-entry. Clinical studies have
also shown that MWF is associated with an increased
risk for ventricular arrhythmias (12–14,17). Other
studies supported the use of T1 mapping in predicting
ventricular arrhythmias in ICD recipients (29).
Physicians may refer to the DANISH study as a
basis for making decisions on the choice of device
therapy in patients with NICM. We should consider,
however, that DANISH did not use CMR for tissue
characterization of the underlying cardiomyopathy.
In the present study, we showed that NICM with
MWF behaves differently than NICM without MWF.
On this basis, MWF should be regarded as a “high-
risk feature” in patients with NICM and raises the
possibility that patients with MWF may derive a
clinical beneﬁt from CRT-D over CRT-P.
STUDY LIMITATIONS. This study has the typical
limitations of an observational study. Rather than by
study design, the choice of device therapy in pa-
tients with NICM was governed by U.K. guidelines,
which, prior to 2014, did not recommend CRT-D for
patients with NICM (18). Because we did not use
telemonitoring, we cannot clarify whether patients
who were coded as having died from pump failure
could have died from arrhythmic events. Impor-
tantly, this was an observational study, and any
parallels or discrepancies with randomized,
controlled trials should be interpreted with
caution. We did not use quantiﬁcation of myocardial
scar, but we cannot discount the possibility that
semiautomatic methods (30) may further improve
CENTRAL ILLUSTRATION Cardiac Resynchronization Therapy in Nonischemic Cardiomyopathy
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We sought to determine whether cardiac resynchronization therapy–deﬁbrillation (CRT-D) was superior to cardiac resynchronization therapy–pacing
(CRT-P) in patients with nonischemic cardiomyopathy (NICM) with or without midwall ﬁbrosis. (A) Four-chamber and short-axis inversion recovery late
gadolinium enhancement cardiac magnetic resonance images show midwall enhancement (yellow arrows) in the interventricular septum, typical of
midwall ﬁbrosis. (B) Survival curves for patients with NICM demonstrated that CRT-D was superior to CRT-P for total mortality and the presence of
midwall ﬁbrosis affected the likelihood of sudden cardiac death.
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1225risk stratiﬁcation. Unfortunately, only 52 patients
underwent CRT implantation using a quadripolar
lead. Although we found no interaction between lead
type and outcomes, this might be due to statistical
underpowering. The lack of systematic, prospective
collection of device interrogation data might also
have led to an underestimation of the overall beneﬁt
from CRT-D. Novel CMR techniques, such as map-
ping of border zone of scar and scar morphology,
which were not addressed in the present study,
might add to the risk stratiﬁcation.CONCLUSIONS
In our total population of patients with CMR-
conﬁrmed NICM, CRT-D was superior to CRT-P. This
beneﬁt, however, was evident in þMWF but
not MWF patients. In the total study population,
MWF emerged as an independent predictor of mor-
tality and morbidity in patients with NICM undergo-
ing CRT, a relationship that was mediated by pump
failure, SCD, and ventricular arrhythmias. These
ﬁndings reinforce a tailored approach in the choice of
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Patients with NICM who
have MWF detected by CMR face worse clinical out-
comes than those without MWF. Hence, patients with
MWF may beneﬁt from devices with deﬁbrillation
capability (CRT-D).
TRANSLATIONAL OUTLOOK: Prospective trials
are needed to conﬁrm the utility of CMR for detection
of MWF as a guide to selection of patients with NICM
for device-based therapies.
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1226device in patients with NICM and support the use of
CMR in risk stratiﬁcation. Randomized controlled
trials of CRT-D versus CRT-P in patients with
NICM with or without myocardial scar should be
considered.
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